Approach

Summary

Licensing status

Publication and contact information

Assays & screens

Ex vivo model of HIV latency to screen latency-reversing agents

An ex vivo model of latent HIV in patient T cells could help predict clinical efficacy of latency-reversing agents. In a coculture of
T cells from patients latently infected with HIV and healthy controls, latency-reversing compounds previously shown to be effective in vitro failed to induce spreading of the virus to noninfected cells, indicating that they do not reverse viral latency ex vivo. In latently infected cells from patients on antiretroviral therapy, all tested compounds failed to reverse latency as measured by HIV mRNA transcription except bryostatin-1, which is toxic in vivo. Next steps include identifying new agents or combinations that reactivate latent HIV in patient cells.

SciBX 7(16); doi:10.1038/scibx.2014.470
Published online April 24, 2014

Unpatented; licensing status not applicable

Bullen, C.K. et al. Nat. Med.; published online March 23, 2014;
doi:10.1038/nm.3489
Contact: Robert F. Siliciano, The Johns Hopkins University School of Medicine, Baltimore, Md.
e-mail:

rsiliciano@jhmi.edu